Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GHTF to release two guidances on inspections

This article was originally published in The Silver Sheet

Executive Summary

A new "N33" guidance document that provides a framework for auditors writing reports after conducting a quality systems inspection will soon be released by the Global Harmonization Task Force's (GHTF) Study Group 4. "This document gives us a common format to work from so that if I at FDA am at my desk and I get 50 of these reports to read from around the world ... I know that I'm coming up on the same information in the same format" as fellow auditors in different countries, said Jan Welch, a consumer safety officer in CDRH's Office of Compliance, and secretary of the study group. She said a draft revision of "N28" - a guidance document on facility inspections that takes newer versions of global standards into account - will be released at the same time. "We very much are interested in getting comments from all of you ... on this document," Welch told GHTF participants

You may also be interested in...



Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT036148

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel